Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.78 and traded as low as $3.47. Cryo-Cell International shares last traded at $3.47, with a volume of 3,180 shares changing hands.

Cryo-Cell International Stock Performance

The company has a market cap of $27.97 million, a price-to-earnings ratio of -11.19 and a beta of 0.54. The stock’s fifty day moving average is $3.32 and its two-hundred day moving average is $3.78.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its earnings results on Friday, February 27th. The company reported ($0.47) earnings per share for the quarter. The company had revenue of $7.84 million for the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is currently owned by institutional investors and hedge funds.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.